GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as a treatment for relapsed or refractory multiple myeloma. This pivotal trial demonstrated a statistically significant progression-free survival (PFS) benefit for Blenrep combined with bortezomib and dexamethasone (BorDex) against the daratumumab plus BorDex regimen. Trial Details and Efficacy […]
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA) for CARVYKTI (ciltacabtagene autoleucel or cilta-cel), based on data obtained from the CARTITUDE-4 study (NCT04181827). This study focuses on the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who have undergone one to three prior […]
Natco Pharma Limited has announced the Canadian launch of PrNAT-LENALIDOMIDE Capsules, a generic version of Celgene Corporation’s cancer drug Revlimid. The launch was announced earlier this month by the Indian pharma company’s Canadian subsidiary — Natco Pharma (Canada). PrNAT-LENADLIDOMIDE in combination with dexamethasone is approved by Health Canada for the treatment of multiple myeloma in […]
DARZALEX FASPRO FDA approval for AL amyloidosis : Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured approval from the US Food and Drug Administration (FDA) for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd) for the treatment of light chain (AL) amyloidosis, which has been newly diagnosed in […]
Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed to meet the primary endpoint of progression-free survival (PFS). The late-stage trial assessed the combination of NINLARO (ixazomib) with lenalidomide and dexamethasone in comparison to lenalidomide and dexamethasone plus placebo […]
DKd regiment FDA approval for multiple myeloma : Janssen Pharmaceutical Companies of Johnson & Johnson and Amgen have been granted an expanded approval from the US Food and Drug Administration (FDA) for the DKd regimen comprising the former’s DARZALEX (daratumumab) and the latter’s Kyprolis (carfilzomib) plus dexamethasone for the treatment of multiple myeloma. The approval […]
The University of Oxford said that steroid dexamethasone has succeeded in reducing death in the ongoing RECOVERY trial in hospitalized patients with severe respiratory complications of COVID-19. The RECOVERY trial was launched in March 2020 as a randomized clinical trial to evaluate a range of potential treatments for coronavirus, including low-dose dexamethasone, which is a steroid […]
RECOVERY coronavirus trial : University of Oxford researchers in the UK have initiated a coronavirus clinical trial called the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial. The RECOVERY clinical trial, which has enrolled the first patients, will test the effects of potential drug treatments for COVID-19 patients admitted to hospitals. The objective of the clinical […]
CANDOR clinical trial results : Amgen said that a phase 3 study assessing Kyprolis (carfilzomib) in combination with dexamethasone and Johnson & Johnson’s Darzalex (daratumumab) (KdD) compared to Kyprolis and dexamethasone alone (Kd), called CANDOR, met its primary endpoint of progression-free survival (PFS) in multiple myeloma patients. The Amgen clinical trial featured 466 relapsed or […]
The United States Food and Drug Administration (FDA) has granted approval for a new once-weekly dosing regimen of Amgen’s Kyprolis (carfilzomib) in combination with dexamethasone for patients with relapsed or refractory multiple myeloma. This new regimen, known as the once-weekly Kd70, involves administering Kyprolis at a dose of 70 mg/m². The approval follows the results […]